RFI: Beacon Program - Medical Countermeasure (MCM) Candidate Integration and Subcontractor Management

Questions & Answers / Clarifications

This document contains a list of questions posed by potential vendors regarding the "Beacon" opportunity, likely seeking clarification on various aspects of the potential contract. It serves to gather information from industry to inform the government's acquisition strategy.

• Team Size and Expertise: Inquiries about the size and expertise of the vendor's team.
• Teaming with Developers: Questions regarding willingness to team with Government-identified drug developers.
• Government Contract Experience: Assessment of experience managing government contracts, specifically as a prime contractor.
• Contract Mechanisms: Experience with various contract types such as OTA, CRADA, and IDIQ.
• Subcontractor Management: Details on selecting, qualifying, and managing subcontractors, including mechanisms for quick award.
• Regulatory Experience: Inquiries about in-house regulatory experience.
• Risk Management: How the company identifies, assesses, and mitigates risks.
• Supply Chain Management: Processes for managing the supply chain.
• Medical Countermeasure Development: Experience managing programs related to medical countermeasures and advancing projects under the FDA Animal Rule.
• Testing Facilities: Existing relationships with in vivo testing facilities.
• Military Use Drug Development: Experience managing drug development for military applications.
• Operational Relevancy Testing: Experience overseeing testing to determine operational use of equipment/drugs.
• Data Handling and Security: Capability to handle Controlled Unclassified Information (CUI) and Secret data, including user training and system security standards.
• Intellectual Property Management: Processes for managing intellectual property and data security.
• AI Utilization: How AI is utilized on contracts.
• Technical, Regulatory, and Quality Assurance: Methods for ensuring requirements are met.
• Issue Handling: Procedures for handling unexpected issues with subcontractors.
• Government Input: Whether the government can require specific contractors or have input in final decisions.
• Case Studies: Availability of anonymized case studies with timelines, budgets, and outcomes.
• CRO/CDMO/Lab Network: Existence of a pre-qualified network of research organizations.
• Tech Transfers: Management of technology transfers between subcontractors.
• Document Control: Procedures for document control.
• Security Access: Building security access controls.
• Data Control and Sample Handling: Management of data control and sample handling/tracking.
• Quality Management System: Description of the company's Quality Management System.

These questions indicate areas where potential bidders may need to provide detailed information in their proposals or where the government may seek further clarification. The responses to these questions, if provided, would significantly impact the understanding of requirements and evaluation criteria.

Statement of Objectives (SOO)

This document outlines the objectives for the Beacon program, which aims to accelerate the identification and screening of Medical Countermeasure (MCM) candidates through a data-driven approach. The program will conduct non-clinical, clinical, and Chemical, Manufacturing, and Controls (CMC) testing of MCM candidates to reduce development risks and demonstrate effectiveness in simulated operational environments. The government is responsible for identifying and selecting MCM candidates, while the awardee will manage and execute the testing plans by subcontracting with testing performers.

• Program Management: Develop and maintain an Integrated Master Schedule (IMS), establish communication channels, conduct biweekly programmatic and technical meetings, provide monthly, quarterly, and annual reports, develop a Spend Plan, and submit a Risk Management Plan.

• Candidate Testing: Oversee procurement of MCM candidates, test agents, and materials; manage non-clinical and clinical testing (in vitro and in vivo); oversee CMC development; and manage operational relevancy studies.

• Regulatory: Act as Regulatory Sponsor, develop a comprehensive Regulatory Strategy, obtain a Target Product Profile (TPP) for each candidate, manage FDA engagement and submissions, and ensure compliance with regulations (GLP, cGMP).

• Data Management: Manage intellectual property, establish NDAs, implement a Data Management Plan, ensure quality-controlled data generation, and manage data entry into the Government-specified repository (e.g., Metis).

• Deliverables: Include IMS, meeting minutes, various reports (monthly, quarterly, annual, final), Spend Plan, Study Protocols, Regulatory Strategy, TPP, FDA communications, and Data Management Plan.

• Period of Performance: Anticipated 60 months (5 years) from the date of award.

• Place of Performance: Primarily the awardee's facilities, with significant work at subcontractor facilities.

This is a Statement of Objectives (SOO), indicating that a subsequent Statement of Work (SOW) will provide further details. The evaluation criteria are not detailed in this document.

Not specified in this document.

• The government retains final authority over candidate down-selection.
• The awardee's proposed Program Manager is designated as Key Personnel.
• The government reserves the right to conduct on-site audits and inspections.
• The Metis tool, employing artificial intelligence, will be used for candidate data evaluation.